DK3592742T3 - JAK inhibitorer med en 4-leddet heterocyclisk amid - Google Patents

JAK inhibitorer med en 4-leddet heterocyclisk amid Download PDF

Info

Publication number
DK3592742T3
DK3592742T3 DK18711796.5T DK18711796T DK3592742T3 DK 3592742 T3 DK3592742 T3 DK 3592742T3 DK 18711796 T DK18711796 T DK 18711796T DK 3592742 T3 DK3592742 T3 DK 3592742T3
Authority
DK
Denmark
Prior art keywords
membered heterocyclic
jak inhibitors
heterocyclic amide
amide
jak
Prior art date
Application number
DK18711796.5T
Other languages
English (en)
Inventor
Paul R Fatheree
Gary E L Brandt
Cameron Smith
Steven D E Sullivan
Orden Lori Jean Van
Melanie A Kleinschek
Glenn D Crater
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Application granted granted Critical
Publication of DK3592742T3 publication Critical patent/DK3592742T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18711796.5T 2017-03-09 2018-03-08 JAK inhibitorer med en 4-leddet heterocyclisk amid DK3592742T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (1)

Publication Number Publication Date
DK3592742T3 true DK3592742T3 (da) 2021-08-09

Family

ID=61683956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18711796.5T DK3592742T3 (da) 2017-03-09 2018-03-08 JAK inhibitorer med en 4-leddet heterocyclisk amid

Country Status (20)

Country Link
US (10) US10208040B2 (da)
EP (2) EP3592743A1 (da)
JP (2) JP6974487B2 (da)
KR (2) KR102526764B1 (da)
CN (2) CN110382498B (da)
AR (2) AR111242A1 (da)
AU (2) AU2018231035B2 (da)
BR (2) BR112019018648A2 (da)
CA (1) CA2997772A1 (da)
DK (1) DK3592742T3 (da)
EA (2) EA037748B1 (da)
ES (1) ES2882186T3 (da)
IL (2) IL268689B2 (da)
MX (2) MX2019010539A (da)
PH (2) PH12019501941A1 (da)
PT (1) PT3592742T (da)
SG (2) SG11201907544VA (da)
TW (2) TWI779016B (da)
WO (2) WO2018165395A1 (da)
ZA (2) ZA201905585B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
PT3592742T (pt) * 2017-03-09 2021-07-30 Theravance Biopharma R&D Ip Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112019022665A2 (pt) 2017-05-01 2020-05-19 Theravance Biopharma R&D Ip Llc métodos de tratamento usando um composto inibidor de jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
ES2955717T3 (es) * 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
CA3113667A1 (en) 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as jak inhibitor
BR112021016751B8 (pt) 2019-02-25 2023-11-21 Henan Medinno Pharmaceutical Tech Co Ltd Compostos, composições farmacêuticas e usos dos compostos
EP3934651A1 (en) 2019-03-05 2022-01-12 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN113121509B (zh) * 2019-12-30 2024-04-26 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
EP4359402A1 (en) * 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011084486A1 (en) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド
AU2015260905A1 (en) 2014-05-14 2016-12-01 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3592742T (pt) * 2017-03-09 2021-07-30 Theravance Biopharma R&D Ip Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
BR112019022665A2 (pt) 2017-05-01 2020-05-19 Theravance Biopharma R&D Ip Llc métodos de tratamento usando um composto inibidor de jak
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors

Also Published As

Publication number Publication date
US20210269436A1 (en) 2021-09-02
BR112019018649A2 (pt) 2020-04-07
US10954237B2 (en) 2021-03-23
CN110461839B (zh) 2022-08-23
US20200216447A1 (en) 2020-07-09
AR111241A1 (es) 2019-06-19
EP3592743A1 (en) 2020-01-15
ES2882186T3 (es) 2021-12-01
EA201992128A1 (ru) 2020-01-29
JP2020510010A (ja) 2020-04-02
US20180258087A1 (en) 2018-09-13
AU2018231032A1 (en) 2019-09-05
JP6974487B2 (ja) 2021-12-01
WO2018165395A1 (en) 2018-09-13
US10196393B2 (en) 2019-02-05
US10392386B2 (en) 2019-08-27
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
US10519153B2 (en) 2019-12-31
KR102526764B1 (ko) 2023-04-27
TW201837037A (zh) 2018-10-16
US10550118B2 (en) 2020-02-04
KR102533646B1 (ko) 2023-05-17
IL268689B2 (en) 2023-02-01
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
SG11201907840RA (en) 2019-09-27
ZA201905618B (en) 2021-05-26
ZA201905585B (en) 2020-05-27
US20220289737A1 (en) 2022-09-15
EP3592742A1 (en) 2020-01-15
KR20190127796A (ko) 2019-11-13
CA2997772A1 (en) 2018-09-09
US10208040B2 (en) 2019-02-19
MX2019010539A (es) 2019-10-21
PT3592742T (pt) 2021-07-30
AU2018231032A8 (en) 2019-10-17
EA201992126A1 (ru) 2020-02-05
US20180258088A1 (en) 2018-09-13
NZ756823A (en) 2021-04-30
EA037261B1 (ru) 2021-03-01
SG11201907544VA (en) 2019-09-27
TW201840560A (zh) 2018-11-16
US11667637B2 (en) 2023-06-06
CN110382498A (zh) 2019-10-25
PH12019501985A1 (en) 2020-10-05
IL268679A (en) 2019-10-31
EP3592742B1 (en) 2021-05-19
BR112019018648A2 (pt) 2020-06-16
AR111242A1 (es) 2019-06-19
CN110382498B (zh) 2022-07-12
US11878977B2 (en) 2024-01-23
US11453668B2 (en) 2022-09-27
US20190127371A1 (en) 2019-05-02
IL268679B (en) 2021-10-31
JP2020510015A (ja) 2020-04-02
US20200181141A1 (en) 2020-06-11
TWI754019B (zh) 2022-02-01
US11254669B2 (en) 2022-02-22
KR20190127798A (ko) 2019-11-13
IL268689B (en) 2022-10-01
IL268689A (en) 2019-10-31
AU2018231032B2 (en) 2021-08-19
AU2018231035B2 (en) 2021-09-09
AU2018231035A1 (en) 2019-09-05
EA037748B1 (ru) 2021-05-18
CN110461839A (zh) 2019-11-15
US20230063643A1 (en) 2023-03-02
JP7134990B2 (ja) 2022-09-12
US20190119275A1 (en) 2019-04-25
TWI779016B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
DK3592742T3 (da) JAK inhibitorer med en 4-leddet heterocyclisk amid
HK1253559A1 (zh) 作為組蛋白脫甲基酶抑制劑的吡咯烷酰胺化合物
DK3436444T3 (da) Heterocyklisk forbindelse
HK1245244A1 (zh) 作爲激酶抑制劑的雜環酰胺
DK3883936T3 (da) Nye heterocykliske forbindelser
DK3233851T3 (da) Pesticidaktive heterocykliske derivater med svovlindeholdende substituenter
BR112017002598A2 (pt) derivados heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017003366A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
IL279949A (en) Heterocyclic MCT4 inhibitors
HK1251224A1 (zh) 雙環雜環酰胺衍生物
DK3461812T3 (da) N-(5-(biphen-4-ylmethyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase
BR112016022043A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112016022217A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017014894A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112018001413A2 (pt) derivados heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
IL259971B (en) Anthelmintic heterocyclic amides
BR112017011306A2 (pt) derivados heterocíclicos de amida com substituintes contendo enxofre ativos em termos pesticidas
BR112018006197A2 (pt) derivados heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
IL266326A (en) Disubstituted heterocyclic bicyclic derivatives are useful for romk channel inhibition
DK3374720T3 (da) Anordning med drejeplade til tilførsel af mellemkalibret ammunition
DK3472149T3 (da) Heterocykliske prolinamidderivater
DK3454568T3 (da) Mikrofon-forforstærker med polariseringsspændingsforsyning
EP3514149A4 (en) HETEROCYCLIC AMIDE COMPOUND
IT201600074606A1 (it) New benzo-N-hydroxy amide compounds having antitumor activity
MA47730A (fr) Inhibiteurs de bêta-sécrétase